Right Treatment, Right Patient, Right Time
Through our research into the tumor microenvironment, we are learning more 博彩app软件 how a patient’s dynamic tumor biology can be used as a guide for treatment decisions throughout his or her cancer journey. We continue to investigate the role of PD-L1 , tumor mutational burden , and gene signatures of inflammation, and other potentially predictive biomarkers – both tumor and peripheral biomarkers – to better inform and predict the benefit of current and future approaches. Additionally, our teams continue to evaluate potential diagnostic tools to help identify those biomarkers in patients leveraging less-invasive methods such as liquid biopsy.
To learn more 博彩app软件 how 博彩app软件下载 Myers Squibb is exploring the research behind why some people respond to immunotherapy and others do not, click here.